

IN THE CLAIMS

Please amend the claims as follows:

1. **(Original)** A coprecipitate of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and a water-soluble polymer.
2. **(Original)** The coprecipitate according to claim 1, which has broad peaks at the diffraction angles (2θ) in the vicinity of: 4.6°, 10.5°, and 26.0° in a powder X-ray diffraction pattern.
3. **(Currently amended)** The coprecipitate according to claim 1 ~~or 2~~, which has a broad exothermic peak at 120 – 180°C and a sharp endothermic peak at 220 – 230°C in a thermal analysis using a differential scanning calorimetry.
4. **(Currently amended)** The coprecipitate according to ~~any one of~~ claim[s] 1 ~~to 3~~, which has a solubility, in water at 37°C, of 14 to 20 µg/mL, as indicated by the concentration of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine.
5. **(Currently amended)** The coprecipitate according to ~~any one of~~ claim[s] 1 ~~to 4~~, wherein the weight mixing ratio of 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and the water-soluble polymer is from 1:0.05 to 1:1.
6. **(Currently amended)** The coprecipitate according to ~~any one of~~ claim[s] 1 ~~to 5~~, wherein the water-soluble polymer is a cellulosic water-soluble polymer.

7. **(Original)** The coprecipitate according to claim 6, wherein the water-soluble polymer is methyl cellulose or hydroxypropylmethyl cellulose.
8. **(Currently amended)** A pharmaceutical composition for oral administration, comprising the coprecipitate according to ~~any one of~~ claim[s] 1 ~~to~~ 7, and a pharmaceutically acceptable carrier.
9. **(Currently amended)** The coprecipitate according to ~~any one of~~ claim[s] 1 ~~to~~ 7, which is used as a pharmaceutical bulk.
10. **(Currently amended)** An antiallergic medicine comprising the coprecipitate according to ~~any one of~~ claim[s] 1 ~~to~~ 7.
11. **(Currently amended)** A process for producing the coprecipitate according to ~~any one of~~ claim[s] 1 ~~to~~ 7, comprising the steps of:
 - mixing a water-soluble organic solvent solution containing 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7,8-dimethoxy-4(5H),10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and a liquid medium containing water as a main component to give a mixture, wherein the coprecipitate is produced, and
 - isolating the coprecipitate from the mixture,wherein the water-soluble organic solvent solution and/or the liquid medium comprise/comprises a water-soluble polymer.
12. **(Original)** The process for producing the coprecipitate according to claim 11, wherein the water-soluble organic solvent is dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, or N-methyl-2-pyrrolidone.
13. **(Currently amended)** Use of the coprecipitate according to ~~any one of~~ claim[s] 1 ~~to~~ 7 for the production of a pharmaceutical composition.

14. **(Currently amended)** Use of the coprecipitate according to ~~any one of~~ claim[s] 1 to 7 for the production of an antiallergic medicine.

15. **(Currently amended)** A method for preventing or treating an allergic disease, comprising administering the coprecipitate according to ~~any one of~~ claim[s] 1 ~~to 7~~ to an animal including a human.